No Data
No Data
FDA Grants Orphan Drug Status to UniQure's AMT-191, Aiming to Treat Fabry Disease
UniQure Biopharma Granted Orphan Drug Designation For Its 'Adeno-associated Viral Vector Serotype 5 Encoding Human Alpha-galactosidase A' For The Treatment Of Fabry Disease
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright analyst Patrick Trucchio maintains $uniQure NV(QURE.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 29.0%
HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target
UniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
UniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know